---
figid: PMC9687343__biomedicines-10-02988-g004
figtitle: 'Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic
  Targeting of Cancer Stem Cells and the Tumor Microenvironment'
organisms:
- Mus musculus
- Paraechinus aethiopicus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC9687343
filename: biomedicines-10-02988-g004.jpg
figlink: /pmc/articles/PMC9687343/figure/biomedicines-10-02988-f004/
number: F4
caption: A schema showing the effect of the paracrine renin–angiotensin system (RAS)
  and its convergent signaling pathways on the tumor microenvironment to influence
  cellular proliferation, invasiveness, and cell survival in cancer development. The
  RAS interacts with downstream pathways, such as the Ras/RAF/MEK/ERK (light blue)
  pathway and the PI3K/AKT/mTOR (dark blue) pathway, and the up-stream Wnt/β-catenin
  pathway (intermediate blue) that influence cellular proliferation, migration, inhibition
  of apoptosis, migration, and invasion (see text). PRR, pro-renin receptor; LRP6,
  low-density lipoprotein receptor-related protein; Fzd, frizzled receptor; Cath G,
  cathepsin G; Cath B, cathepsin B; Cath D, cathepsin D; ACE1, angiotensin-converting
  enzyme 1; ACE2, angiotensin-converting enzyme 2; ADP, adenosine diphosphate; AGT,
  angiotensinogen; ATP, adenosine triphosphate; Ang(1–7), angiotensin (1–7); Ang(1–9),
  angiotensin (1–9); AP-A, aminopeptidase-A; NEP, neutral endopeptidase; AP-N, aminopeptidase-N;
  ATI, angiotensin I; ATII, angiotensin II; ATIII, angiotensin III; ATIV, angiotensin
  IV; AT1R, angiotensin II receptor 1; AT2R, angiotensin II receptor 2; AT4R, angiotensin
  II receptor 4; MrgD, Mas-related-G protein coupled receptor; MasR, Mas receptor;
  mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa B; TGF-β1, transforming
  growth factor-β1; V-ATPase, vacuolar H+-adenosine triphosphate. Adapted from Cancers
  []. Diagram recreated with BioRender.com, accessed on 1 November 2022.
papertitle: 'Cancer Metastasis and Treatment Resistance: Mechanistic Insights and
  Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment.'
reftext: Ethan J. Kilmister, et al. Biomedicines. 2022 Nov;10(11):2988.
year: '2022'
doi: 10.3390/biomedicines10112988
journal_title: Biomedicines
journal_nlm_ta: Biomedicines
publisher_name: MDPI
keywords: cancer stem cell | metastasis | treatment resistance | tumor microenvironment
  | renin-angiotensin system
automl_pathway: 0.935616
figid_alias: PMC9687343__F4
figtype: Figure
redirect_from: /figures/PMC9687343__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9687343__biomedicines-10-02988-g004.html
  '@type': Dataset
  description: A schema showing the effect of the paracrine renin–angiotensin system
    (RAS) and its convergent signaling pathways on the tumor microenvironment to influence
    cellular proliferation, invasiveness, and cell survival in cancer development.
    The RAS interacts with downstream pathways, such as the Ras/RAF/MEK/ERK (light
    blue) pathway and the PI3K/AKT/mTOR (dark blue) pathway, and the up-stream Wnt/β-catenin
    pathway (intermediate blue) that influence cellular proliferation, migration,
    inhibition of apoptosis, migration, and invasion (see text). PRR, pro-renin receptor;
    LRP6, low-density lipoprotein receptor-related protein; Fzd, frizzled receptor;
    Cath G, cathepsin G; Cath B, cathepsin B; Cath D, cathepsin D; ACE1, angiotensin-converting
    enzyme 1; ACE2, angiotensin-converting enzyme 2; ADP, adenosine diphosphate; AGT,
    angiotensinogen; ATP, adenosine triphosphate; Ang(1–7), angiotensin (1–7); Ang(1–9),
    angiotensin (1–9); AP-A, aminopeptidase-A; NEP, neutral endopeptidase; AP-N, aminopeptidase-N;
    ATI, angiotensin I; ATII, angiotensin II; ATIII, angiotensin III; ATIV, angiotensin
    IV; AT1R, angiotensin II receptor 1; AT2R, angiotensin II receptor 2; AT4R, angiotensin
    II receptor 4; MrgD, Mas-related-G protein coupled receptor; MasR, Mas receptor;
    mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa B; TGF-β1, transforming
    growth factor-β1; V-ATPase, vacuolar H+-adenosine triphosphate. Adapted from Cancers
    []. Diagram recreated with BioRender.com, accessed on 1 November 2022.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - CTNNB1
  - LRP6
  - ANPEP
  - SERPINC1
  - ENPEP
  - NFKB1
  - TGFB1
  - AGTR2
  - PGR-AS1
  - ACE2
  - AGTR1
  - ACE
  - MAPK3
  - MAPK1
  - CMA1
  - NECTIN1
  - NR1I2
  - ATP6AP2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - AGT
  - AGXT
  - MRGPRD
  - Ctnnb1
  - Lrp6
  - Atp6v0d2
  - Anpep
  - Serpinc1
  - Enpep
  - Nfkb1
  - Tgfb1
  - Serpinb9d
  - Ace2
  - Agtrap
  - Mapk3
  - Mapk1
  - Nectin1
  - Atp6ap2
  - Pik3r1
  - Akt1
  - Mtor
  - Agt
  - Agxt
  - Mgmt
  - Mas1
  - Mrgprd
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - fz
  - arm
  - arr
  - VhaSFD
  - Vha26
  - Vha55
  - Vha16-1
  - apn
  - en
  - Sap-r
  - Dif
  - dl
  - Rel
  - Ace
  - ACE1
  - Cp38
  - rl
  - cathD
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - agt
  - ctnnb1
  - lrp6
  - lrp5
  - tgfb1a
  - ace2
  - mapk3
  - mtor
---
